Breaking News Instant updates and real-time market news.

AMGN

Amgen

$171.91

-2.75 (-1.57%)

18:03
04/24/18
04/24
18:03
04/24/18
18:03

Amgen CEO says Q1 performance driven by new, recently launched products

"Amgen's strong first-quarter performance was driven by our new and recently launched products, all of which delivered double-digit, volume-driven growth," said Robert Bradway, chairman and CEO. "We look forward to further expanding our new product portfolio with the expected U.S. launch of Aimovig, our first-in-class migraine prevention therapy, in the second quarter and the European launch of AMGEVITA, our first biosimilar, later this year."

  • 24

    Apr

  • 24

    Apr

  • 30

    Apr

  • 17

    May

  • 22

    May

  • 28

    May

AMGN Amgen
$171.91

-2.75 (-1.57%)

03/12/18
MSCO
03/12/18
NO CHANGE
Target $196
MSCO
Overweight
Enbrel IPR denials lift an overhang on Amgen, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted that on Friday the USPTO's Patent Trial and Appeal Board denied the institution of two IPRs filed by Coherus Biosciences (CHRS) against Enbrel patients 8,063,182 and 8,163,522, which he said removes one near-term overhang on Amgen (AMGN) shares. Harrison noted that he has always viewed the IPRs as a greater risk to Enbrel than a District Court case being brought by Novartis' (NVS) Sandoz division, which is set to begin its trial on April 17, as he has always seen a potential settlement with Sandoz as a reasonable possibility. The analyst keeps his Overweight rating and $196 price target on Amgen shares.
02/20/18
JEFF
02/20/18
NO CHANGE
Target $200
JEFF
Buy
Amgen shares 'very attractive' despite some headline risk, says Jefferies
Jefferies analyst Michael Yee says three upcoming legal and regulatory decisions around Enbrel, Neulasta, and Sensipar could cause potential "headline downside risk" for Amgen shares. However, these are "manageable or somewhat expected," Yee tells investors in a research note. He points out that Amgen has a $10B Dutch Tender underway and an additional $4B buyback authorization. The stock looks "very attractive" at current levels, and Amgen has "significant capital deployment and M&A capabilities," Yee contends. He keeps a Buy rating on the stock with a $200 price target.
02/14/18
PIPR
02/14/18
NO CHANGE
PIPR
Overweight
Amgen added co-pay accumulator risk in annual filing, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond points out that Amgen in its annual filing specifically called out co-pay accumulators as part of its reimbursement risk language, which was not included in previous filings. These relatively recent programs are designed to accelerate shifting of drug cost burdens to patients and manufacturers and appear to have caught both patients and manufacturers by surprise, Raymond tells investors in a research note. While Amgen indicated the near-term impact to Enbrel will be minimal, the issue warrants further monitoring throughout 2018, the analyst contends. He keeps an Overweight rating on Amgen shares.
02/05/18
02/05/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Wells Fargo (WFC) downgraded to Market Perform from Outperform at Keefe Bruyette, to Neutral from Buy at Citi, to Underperform from Outperform at RBC Capital, to Underweight from Neutral at JPMorgan, and two notches to Underweight from Overweight at Morgan Stanley. 2. Dick's Sporting (DKS) downgraded to Underweight from Equal Weight at Barclays with analyst Matthew McClintock saying sentiment on the shares have improved over the past month under the narrative that Dick's could become the next Best Buy (BBY). 3. Amgen (AMGN) downgraded to Neutral from Overweight at Atlantic Equities with analyst Steve Chesney citing relative valuation and more balanced risk/reward on Repatha's commercial trajectory and the of legacy biologics given biosimilar, branded and IP risks. 4. Marathon Petroleum (MPC) and MPLX (MPLX) were downgraded to Hold from Buy at Jefferies. 5. VMware (VMW) downgraded to Neutral from Buy at Citi with analyst Walter Pritchard saying he sees "no easy deal" for Dell and expects the overhang to cap VMware shares around the $138 level. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

FCX

Freeport McMoRan

$14.02

0.3 (2.19%)

, SCCO

Southern Copper

$41.84

0.76 (1.85%)

15:44
09/18/18
09/18
15:44
09/18/18
15:44
Periodicals
Copper prices advance on less harsh tariffs, WSJ says »

Copper prices climbed on…

FCX

Freeport McMoRan

$14.02

0.3 (2.19%)

SCCO

Southern Copper

$41.84

0.76 (1.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:35
09/18/18
09/18
15:35
09/18/18
15:35
Hot Stocks
Breaking Hot Stocks news story  »

CBX trading halted, news…

BIOL

Biolase

$2.06

-0.02 (-0.96%)

15:30
09/18/18
09/18
15:30
09/18/18
15:30
Conference/Events
Biolase to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

TRXC

TransEnterix

$6.04

0.24 (4.14%)

15:25
09/18/18
09/18
15:25
09/18/18
15:25
Options
TransEnterix call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 27

    Nov

MB

Mindbody

$41.15

1.1 (2.75%)

15:25
09/18/18
09/18
15:25
09/18/18
15:25
Conference/Events
Mindbody to host analyst day »

Analyst day to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
09/18/18
09/18
15:17
09/18/18
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
09/18/18
09/18
15:16
09/18/18
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BGS

B&G Foods

$30.40

-1.15 (-3.65%)

15:10
09/18/18
09/18
15:10
09/18/18
15:10
Options
Bearish option flow in B & G Foods as shares drop 3.8% »

Bearish option flow in B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 06

    Nov

15:10
09/18/18
09/18
15:10
09/18/18
15:10
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

YELP

Yelp

$50.19

3.905 (8.44%)

15:05
09/18/18
09/18
15:05
09/18/18
15:05
Options
Yelp call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VKTX

Viking Therapeutics

$20.35

9.95 (95.67%)

14:58
09/18/18
09/18
14:58
09/18/18
14:58
Recommendations
Viking Therapeutics analyst commentary  »

Viking price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 01

    Oct

ACHV

Achieve Life Sciences

$2.55

-0.05 (-1.92%)

14:56
09/18/18
09/18
14:56
09/18/18
14:56
Conference/Events
Achieve Life Sciences to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$362.55

12.31 (3.51%)

, VIA

Viacom

$33.80

0.05 (0.15%)

14:52
09/18/18
09/18
14:52
09/18/18
14:52
Hot Stocks
Netflix working on live-action version of 'Avatar: The Last Airbender' »

Netflix (NFLX) confirmed…

NFLX

Netflix

$362.55

12.31 (3.51%)

VIA

Viacom

$33.80

0.05 (0.15%)

VIAB

Viacom

$30.26

0.2 (0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 16

    Oct

BX

Blackstone

$37.63

0.53 (1.43%)

14:47
09/18/18
09/18
14:47
09/18/18
14:47
Conference/Events
Blackstone to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 25

    Sep

ING

ING Group

$13.00

0.05 (0.39%)

14:46
09/18/18
09/18
14:46
09/18/18
14:46
Syndicate
Breaking Syndicate news story on ING Group »

ING Group files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNST

Constellation Pharmaceuticals

$7.01

-0.64 (-8.37%)

14:44
09/18/18
09/18
14:44
09/18/18
14:44
Conference/Events
Constellation Pharmaceuticals management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 21

    Sep

NTDOY

Nintendo

$0.00

(0.00%)

14:41
09/18/18
09/18
14:41
09/18/18
14:41
Hot Stocks
Nintendo offering Fortnite bundle for Switch »

Nintendo of America…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KO

Coca-Cola

$46.06

-0.26 (-0.56%)

14:40
09/18/18
09/18
14:40
09/18/18
14:40
Hot Stocks
Coca-Cola acquires Australian maker of MOJO Kombucha, terms undisclosed »

The Coca-Cola Company has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

SPWR

SunPower

$7.43

0.85 (12.92%)

14:35
09/18/18
09/18
14:35
09/18/18
14:35
Hot Stocks
SunPower spikes higher after receiving solar tariff exclusion »

Shares of solar solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABBV

AbbVie

$93.60

-1.77 (-1.86%)

14:35
09/18/18
09/18
14:35
09/18/18
14:35
Options
AbbVie put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAIC

SAIC

$77.37

-0.58 (-0.74%)

14:30
09/18/18
09/18
14:30
09/18/18
14:30
Conference/Events
SAIC management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

CPA

Copa Holdings

$79.77

-0.23 (-0.29%)

14:29
09/18/18
09/18
14:29
09/18/18
14:29
Conference/Events
Copa Holdings to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABBV

AbbVie

$94.29

-1.08 (-1.13%)

14:29
09/18/18
09/18
14:29
09/18/18
14:29
Periodicals
Citron reiterates $60 AbbVie target, says lawsuit 'least of the problems' »

Citron Research just…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIPS

Vipshop

$6.06

0.07 (1.17%)

14:25
09/18/18
09/18
14:25
09/18/18
14:25
Options
Vipshop call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDEN

Golden Entertainment

$26.96

0.51 (1.93%)

14:21
09/18/18
09/18
14:21
09/18/18
14:21
Conference/Events
Golden Entertainment management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.